Patients with schizophrenia were randomly assigned to AL 441 mg, AL 882 mg, or placebo intramuscularly. Body weight, body mass index, fasting blood glucose and serum lipids, glycosylated hemoglobin (HbA1c), and prolactin were the parameters evaluated for 12 weeks. Treatment-emergent adverse events (AEs) were used for safety evaluations. Here, PRL is linked to schizophrenia.